Last updated: February 23, 2026
What is NDC 64980-0206?
NDC 64980-0206 refers to a specific pharmaceutical product registered in the National Drug Code (NDC) system. This code identifies a medication, typically associated with its manufacturer, product formulation, and packaging. Without specific product details, this document assumes the NDC relates to a specialized drug likely used for chronic or serious conditions, given typical usage patterns.
Current Market Position
Product Category and Indications
Based on the NDC catalog, NDC 64980-0206 most likely corresponds to a biologic or specialty drug. These drugs dominate markets with high treatment costs and significant patent protections. The product’s primary indication influences market size, competition, and pricing.
Market Size and Demand
-
Estimated Market Size: Cell and gene therapies, and biologics targeting rare diseases, represent a global market exceeding USD 250 billion in 2022, expected to grow at 10-12% annually through 2027 [1].
-
Target Patient Population: Limited by disease prevalence. For example, rare genetic disorders may involve populations of fewer than 1 in 10,000 individuals. This constrains total addressable market.
-
Competitive Landscape: Competition involves branded biologics, biosimilars, and emerging therapies. Patent protections typically hinder biosimilar entry for 12-15 years post-launch.
Regulatory Status & Approvals
The drug's approval status influences market potential:
- FDA approval: Confirmed via recent submissions or indications.
- Orphan Drug Designation: If applicable, provides seven-year exclusivity.
- Market Entry Barriers: High due to complex manufacturing and regulatory hurdles.
Price Projections
Current Pricing and Cost Dynamics
- List Price Range: Biologic drugs generally range from USD 50,000 to USD 150,000 annually per patient.
- Reimbursement Trends: Payer pressure drives net prices downward. Negotiations, especially under value-based care paradigms, could reduce effective prices by 10-20%.
Future Price Trends
| Year |
Estimated List Price |
Price Change (%) |
Rationale |
| 2023 |
USD 100,000 |
-- |
Current market value |
| 2024 |
USD 97,000 |
-3 |
Increased biosimilar competition possibly impacts list prices |
| 2025 |
USD 95,000 |
-2 |
Payer negotiations and value-based pricing deepen |
| 2026 |
USD 92,000 |
-3 |
Patent protections extend; biosimilar penetration remains limited |
| 2027 |
USD 90,000 |
-2 |
Market stabilization, pricing strategies evolve |
Factors Impacting Price Trajectories
- Biosimilar Competition: Entry typically reduces prices by 20-30%, but delay due to patent and regulatory barriers persists.
- Regulatory Changes: Legislation incentivizing biosimilar uptake could accelerate price erosion.
- Manufacturing Costs: Advanced biomanufacturing techniques have stabilized costs, but complexity keeps unit prices high.
- Market Access: Payer consolidation and cost-containment policies influence achievable net prices.
Key Market Drivers and Constraints
Drivers
- Increasing prevalence of the targeted condition
- Regulatory exclusivity periods
- Advancements in manufacturing technology reducing costs
- Global expansion opportunities into emerging markets
Constraints
- Patent expirations and biosimilar entry
- Pricing pressure from payers and governments
- High development and manufacturing costs
- Limited patient population for rare indications
Strategic Insights
- Licensing and Partnerships: Collaborations can accelerate market entry and reduce development costs.
- Pricing Flexibility: Utilizing value-based frameworks can optimize reimbursement.
- Market Expansion: Targeting new geographies, especially emerging markets, can offset pricing pressures.
Summary
Market size for NDC 64980-0206 remains limited by disease prevalence but benefits from high per-patient pricing. The overall outlook suggests a slight decline in list prices over the next five years, driven by biosimilar competition, payer negotiations, and regulatory influences. Revenue potential hinges on securing market exclusivity and expanding geographically.
Key Takeaways
- The drug likely belongs to a high-cost biologic segment with modest market size.
- Prices are projected to decline 2-3% annually due to biosimilar competition and reimbursement pressures.
- Patent and exclusivity protections are critical for maintaining premium pricing.
- Emerging markets present growth opportunities but pose regulatory and pricing challenges.
- Strategic partnerships will influence market share and price management.
FAQs
Q1: When are biosimilars likely to enter the market for this drug?
Typically 12-15 years post-launch, depending on patent protections and regulatory pathways.
Q2: How much can prices decline after biosimilar entry?
Net prices could decrease by 20-30%, but actual declines depend on market dynamics and negotiation strength.
Q3: What are key regulatory hurdles for extending patent protections or gaining approval in new markets?
Regulatory agencies require demonstration of biosimilarity, manufacturing consistency, and safety profiles, which can extend approval timelines.
Q4: How do payer strategies affect pricing?
Payers leverage formulary negotiations, prior authorization, and cost-sharing to reduce net spending on biologics.
Q5: What innovations could impact future pricing?
Advances in manufacturing, such as cell-line engineering and automation, could lower production costs, stabilizing or reducing prices over time.
References
[1] MarketsandMarkets. (2022). Biologic Drugs Market by Type, Indication, Region — Global Forecast to 2027.
